Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review

M.Z. Lin, B.G.L. Vanneste, Q.W. Yu, Z.B. Chen, J.Y. Peng, X.Y. Cai*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

3 Citations (Web of Science)

Abstract

Objective: Update the last known review, and summarize the definitions, diagnostic criteria, reported risk factors, possible mechanisms and potential biomarkers of hyperprogressive disease ( HPD) under immunotherapy.Background: Immunotherapy is a relatively new systemic therapy adding a new method of treatment of especially advanced cancer patients. In a variety of immunotherapies, however, an unexpected acceleration of tumor growth, known as HPD, is observed in approximately 30% of patients after immune checkpoint inhibitor (ICI) treatment. HPD has a deleterious survival effect on patients and represents an urgent issue for both clinicians and patients. Existing literature has reviewed and summarized the definition, diagnostic criteria, reported risk factors and possible mechanisms of hyperprogression. However, with the gradual deepening of the exploration of HPD, researchers have made significant breakthroughs in elucidating the mechanism and mechanism of HPD and exploring biomarkers.Methods: The search was conducted on Google Scholar and PubMed in January and May of 2021. We searched among English papers with no limitation on the publication year. We have included retrospective studies, case reports and basic researches related to HPD in the collection, we also referred to some review articles on HPD in recent years. A qualitative-interpretive approach was used for data extraction.Conclusions: HPD is considered to be an acceleration of tumor growth after ICI treatment that is not only due to immune infiltration but also due to real disease progression, with an incidence of about 4-30% in all retrospective published studies to date. Currently, the most widely used criteria of HPD contain Response Evaluation Criteria in Solid Tumors (RECIST) and tumor growth rate (TGR) or tumor growth kinetics. The common risk factors and underlying mechanisms of HPD have not yet been fully elucidated. However, based on the poor prognosis of HPD, there have been many advances in the exploration of biomarkers in recent years, like the prediction of HPD, such as LDH levels of peripheral blood, liquid biopsy, and radiomics, etc.
Original languageEnglish
Pages (from-to)3276-3291
Number of pages16
JournalTranslational Lung Cancer Research
Volume10
Issue number7
DOIs
Publication statusPublished - 1 Jul 2021

Keywords

  • Immunotherapy
  • hyperprogressive disease (HPD)
  • hyperprogression (HP)
  • CELL LUNG-CANCER
  • EVALUATION CRITERIA
  • DISEASE
  • GUIDELINES
  • CONTRIBUTES
  • PROGRESSION
  • BLOCKADE
  • THERAPY

Cite this